Bruno D. Chapsal
Research Subjects
Bruno D. Chapsal has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Adam W. Cook
Pfizer-Boulder
1 shared publicationAlex Bergstrom
Pfizer-Boulder
1 shared publicationAlida Eide
Pfizer-Boulder
1 shared publicationAmy L. Crooks
Pfizer-Boulder
1 shared publicationAndrew C. Allen
Pfizer-Boulder
1 shared publicationAnna L. Guarnieri
Pfizer-Boulder
1 shared publication
Latest Publications
- 31 December 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (2) , 224-233
Design of Potent Menin–KMT2A Interaction Inhibitors with Improved In Vitro ADME Properties and Reduced hERG Affinity
Inhibitors of the interaction of menin (MEN1) with lysine methyltransferase 2A (KMT2A) have emerged as novel therapeutic options in the treatment of genetically defined acute leukemias. Herein, we describe the structure-based design, synthesis, and biological evaluation of novel inhibitors of the menin-KMT2A interaction. Our structure-activity relationship campaign focused on achieving high antiproliferative cellular activity while mitigating risks associated with CYP3A4-dependent metabolism and hERG inhibition, which were characterized in some early clinical candidates. Our efforts resulted in the discovery of a triazine-based compound series that inhibited MV4-11 leukemia cell line proliferation with IC50 as low as 13 nM, and selected compounds demonstrated improved in vitro ADME properties, de-risked CYP3A4 dependency, and lower hERG inhibition.
- 31 December 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (2) , 224-233
Design of Potent Menin–KMT2A Interaction Inhibitors with Improved In Vitro ADME Properties and Reduced hERG Affinity
Inhibitors of the interaction of menin (MEN1) with lysine methyltransferase 2A (KMT2A) have emerged as novel therapeutic options in the treatment of genetically defined acute leukemias. Herein, we describe the structure-based design, synthesis, and biological evaluation of novel inhibitors of the menin-KMT2A interaction. Our structure-activity relationship campaign focused on achieving high antiproliferative cellular activity while mitigating risks associated with CYP3A4-dependent metabolism and hERG inhibition, which were characterized in some early clinical candidates. Our efforts resulted in the discovery of a triazine-based compound series that inhibited MV4-11 leukemia cell line proliferation with IC50 as low as 13 nM, and selected compounds demonstrated improved in vitro ADME properties, de-risked CYP3A4 dependency, and lower hERG inhibition.